WNT7A Gene

Migration, Crosslink

📖

WNT7A Gene

active

wiki page Created: 2026-04-02T07:19:28 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-wnt7a

📖 Wiki Page

gene3221 wordssynced 2026-04-02

WNT7A Gene

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2">WNT7A</th></tr>
<tr><td>Symbol</td><td>WNT7A</td></tr>
<tr><td>Full Name</td><td>Wnt Family Member 7A</td></tr>
<tr><td>Chromosome</td><td>3q25.31</td></tr>
<tr><td>NCBI Gene ID</td><td>[7479](https://www.ncbi.nlm.nih.gov/gene/7479)</td></tr>
<tr><td>OMIM</td><td>[601053](https://omim.org/entry/601053)</td></tr>
<tr><td>Ensembl</td><td>[ENSG00000177283](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000177283)</td></tr>
<tr><td>UniProt</td><td>[O95388](https://www.uniprot.org/uniprot/O95388)</td></tr>
<tr><td>Aliases</td><td>WNT7A, Wnt-7A</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/neuroinflammation" style="color:#ef9a9a">Neuroinflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">41 edges</a></td>
</tr>
</table>
</div>

Overview

...

WNT7A Gene

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2">WNT7A</th></tr>
<tr><td>Symbol</td><td>WNT7A</td></tr>
<tr><td>Full Name</td><td>Wnt Family Member 7A</td></tr>
<tr><td>Chromosome</td><td>3q25.31</td></tr>
<tr><td>NCBI Gene ID</td><td>[7479](https://www.ncbi.nlm.nih.gov/gene/7479)</td></tr>
<tr><td>OMIM</td><td>[601053](https://omim.org/entry/601053)</td></tr>
<tr><td>Ensembl</td><td>[ENSG00000177283](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000177283)</td></tr>
<tr><td>UniProt</td><td>[O95388](https://www.uniprot.org/uniprot/O95388)</td></tr>
<tr><td>Aliases</td><td>WNT7A, Wnt-7A</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/neuroinflammation" style="color:#ef9a9a">Neuroinflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">41 edges</a></td>
</tr>
</table>
</div>

Overview

WNT7A encodes a secreted signaling protein that belongs to the Wnt family — a group of highly conserved cysteine-rich glycoproteins essential for embryonic development, tissue homeostasis, and nervous system function. WNT7A activates both canonical (β-catenin-dependent) and non-canonical (β-catenin-independent) Wnt signaling pathways, making it a potent regulator of neuronal development, synaptic plasticity, and neuroprotection[@clevers2006][@logan2004].

In the nervous system, WNT7A plays critical roles in:

Axonal growth and guidance during development
Synapse formation and plasticity
Dopaminergic neuron survival
Neuroprotection against various insults

Given its involvement in multiple neurodegenerative processes, WNT7A has emerged as a potential therapeutic target for Alzheimer's disease (AD), Parkinson's disease (PD), and other neurological disorders[@inestrosa2012][@patel2022].

Normal Function

Wnt Signaling Pathways

WNT7A can activate multiple downstream signaling pathways:

Canonical Wnt/β-catenin Pathway

When WNT7A binds to its receptors (Frizzled receptors + LRP5/6 co-receptors), it prevents β-catenin degradation, allowing β-catenin to translocate to the nucleus and activate target gene transcription. Target genes include:

Axin2
Cyclin D1
c-Myc
Neurogenin family members

Non-Canonical Pathways

WNT7A also activates β-catenin-independent pathways:

Planar Cell Polarity (PCP) pathway — Involves Dishevelled, Vangl, and regulates cytoskeletal organization

Wnt/Ca²⁺ pathway — Activates CaMKII and PKC, influencing synaptic transmission

RhoA/ROCK pathway — Regulates cytoskeletal dynamics and axonal guidance

Mermaid diagram (expand to render)

Roles in Neuronal Development

During development, WNT7A is expressed in the developing brain and spinal cord, where it:

Axon guidance — WNT7A acts as a chemorepulsive cue for developing axons, particularly in the corpus callosum and corticospinal tract

Synaptogenesis — Promotes the formation of excitatory synapses on dendritic spines

Neurogenesis — Influences neural stem cell proliferation and differentiation

Dopaminergic development — Critical for the development and survival of dopaminergic neurons in the substantia nigra

Roles in the Mature Nervous System

In the adult brain, WNT7A continues to play important roles:

Synaptic plasticity — Regulates long-term potentiation (LTP) and memory formation
Cognitive function — Wnt signaling is essential for learning and memory
Neuroprotection — Protects neurons from various insults including oxidative stress and excitotoxicity
Adult neurogenesis — Continues to influence neural stem cells in the hippocampus[@zhang2021]

Expression Pattern

WNT7A exhibits dynamic expression patterns throughout development and in adulthood:

During Development

High expression in the embryonic brain
Present in the ventricular zone (neural stem cell niche)
Expression in developing dopaminergic neurons
Found in growing axons and growth cones

In Adult Brain

Expressed in hippocampus (CA1-CA3, dentate gyrus)
Present in cerebral cortex (layers II-III, V)
Detected in basal forebrain cholinergic neurons
Expressed in cerebellum (Purkinje cells)
Lower but detectable expression in substantia nigra

Cellular Sources

Neurons (both excitatory and inhibitory)
[Astrocytes](/cell-types/astrocytes) Oligodendrocyte precursor cells
Certain neuronal subpopulations

Disease Associations

Alzheimer's Disease

WNT7A and the broader Wnt pathway are deeply implicated in AD pathophysiology[@yang2021][@liu2023]:

Amyloid-beta interaction:

Aβ can disrupt Wnt signaling by multiple mechanisms
WNT7A expression is reduced in AD hippocampus
Restoring Wnt signaling can protect against Aβ toxicity

Tau pathology:

Wnt/β-catenin regulates tau phosphorylation through GSK3β
Dysregulated Wnt signaling contributes to NFT formation
β-catenin loss from nucleus correlates with tau pathology

Synaptic dysfunction:

Wnt signaling is essential for synaptic plasticity
Aβ-induced synaptic deficits involve Wnt pathway disruption
WNT7A can protect against Aβ-induced spine loss

Therapeutic potential:

Wnt pathway activators are being developed for AD
Small molecules that stabilize β-catenin show promise in models
Gene therapy approaches to deliver WNT7A are under investigation

Parkinson's Disease

WNT7A has particular relevance to PD due to its role in dopaminergic neurons[@patron2020]:

Dopaminergic neuroprotection:

WNT7A protects substantia nigra dopaminergic neurons from degeneration
Expression is reduced in PD substantia nigra
Adenoviral WNT7A delivery shows neuroprotective effects in MPTP and 6-OHDA models

Mechanisms of protection:

Activation of Akt/mTOR signaling
Anti-apoptotic effects through Bcl-2 family proteins
Reduction of oxidative stress
Enhanced autophagy clearance of α-synuclein

LRRK2 connection:

LRRK2 mutations (common in familial PD) affect Wnt signaling
WNT7A can compensate for LRRK2 dysfunction in some contexts

Therapeutic strategies:

Wnt pathway agonists for PD
Intranasal delivery of WNT7A
Cell-based therapies expressing WNT7A

Spinal Cord Injury

WNT7A promotes axonal regeneration after spinal cord injury[@mcginley2020]:

WNT7A treatment stimulates axonal sprouting
Promotes functional recovery in animal models
Enhances propriospinal axon regeneration

Adult Neurogenesis

WNT7A plays a crucial role in adult hippocampal neurogenesis[@chen2024]:

Neural stem cells — WNT7A promotes proliferation of neural progenitor cells in the subgranular zone
Dendritic development — WNT7A influences dendritic arborization of new neurons
Synaptic integration — WNT7A facilitates formation of synaptic connections
Memory formation — Adult neurogenesis contributes to hippocampal-dependent memory

Mitochondrial Protection

WNT7A has direct effects on mitochondrial function[@martinez2023]:

Mitochondrial biogenesis — WNT7A stimulates formation of new mitochondria
Oxidative stress protection — WNT7A enhances antioxidant defenses
ATP production — WNT7A improves cellular energy status
Apoptosis prevention — WNT7A inhibits mitochondrial apoptotic pathways

Tau Pathology Interactions

WNT7A and GSK3β have complex interactions relevant to tau pathology[@gomez2023]:

GSK3β regulation — WNT7A can modulate GSK3β activity
Tau phosphorylation — Reduced WNT7A may contribute to increased tau phosphorylation
Therapeutic implications — Restoring WNT7A signaling may reduce tau pathology

Therapeutic Delivery

Novel delivery methods for WNT7A are being explored[@yang2024]:

Extracellular vesicles — EVs can deliver WNT7A across the blood-brain barrier
Viral vectors — AAV-mediated WNT7A expression in development
Cell-based therapies — Engineered cells secreting WNT7A

Other Neurological Conditions

Schizophrenia — Wnt pathway dysregulation implicated
Autism spectrum disorders — Wnt signaling in synaptogenesis relevant
Multiple sclerosis — Wnt pathway in oligodendrocyte differentiation
Stroke — WNT7A provides neuroprotection after ischemia

Therapeutic Implications

Wnt Pathway Modulators

Multiple therapeutic strategies targeting Wnt signaling are in development[@arrazola2019][@marosi2019]:

Small Molecule Activators

Wnt agonists that stabilize β-catenin
Frizzled receptor agonists
Inhibitors of negative regulators (e.g., GSK3β inhibitors)

Biological Approaches

Recombinant WNT7A protein
Gene therapy with WNT7A-expressing vectors
Cell-based therapies (e.g., neural stem cells secreting WNT7A)

Repurposed Drugs

Lithium (GSK3β inhibitor)
Certain NSAIDs (some Wnt effects)
Statins (some Wnt pathway effects)

Mermaid diagram (expand to render)

Challenges and Considerations

Blood-brain barrier — Getting Wnt modulators to the brain is challenging
Off-target effects — Wnt signaling has many roles; global activation may cause concerns
Dose timing — Optimal timing relative to disease progression unclear
Combination therapies — Wnt modulators may work synergistically with other approaches

Animal Models

Wnt7a knockout mice — Show axonal guidance defects, reduced synapse formation
Transgenic overexpression — Enhanced axon regeneration, improved cognitive function
Viral vector models — AAV-mediated WNT7A delivery for neuroprotection studies
Conditional models — Tissue-specific manipulation of Wnt signaling

Key Publications

[Clevers H, Cell 2006](https://doi.org/10.1016/j.cell.2006.10.018) — Wnt/β-catenin signaling review

[Inestrosa NC et al., Cell Tissue Res 2012](https://doi.org/10.1007/s00441-011-1316-1) — Wnt in nervous system development

[Patron LA et al., Neurobiology of Disease 2020](https://doi.org/10.1016/j.nbd.2020.104931) — WNT7A in PD models

[Yang K et al., J Alzheimer's Dis 2021](https://doi.org/10.3233/JAD-210026) — Wnt signaling in AD

[Liu J et al., Pharmacol Res 2023](https://doi.org/10.1016/j.phrs.2023.106773) — Wnt targeting for AD therapy

WNT7A Signaling Pathway: Molecular Mechanisms

Receptor Complex Formation

WNT7A signaling is initiated through binding to a complex of receptors and co-receptors on the cell surface. The primary receptors for WNT7A are the Frizzled (FZD) family of seven-pass transmembrane receptors, which contain a cysteine-rich extracellular domain (CRD) that directly interacts with WNT proteins[@clevers2006][@logan2004].

Frizzled Receptors:

FZD1, FZD5, and FZD7 are the primary receptors for WNT7A in the nervous system
Each FZD receptor contains an N-terminal CRD, seven transmembrane domains, and a C-terminal intracellular tail
The CRD binds WNT7A with varying affinities depending on the receptor subtype

Co-receptors:

LRP5/6 (Low-density lipoprotein Receptor-related Protein 5/6) serve as essential co-receptors for canonical signaling
RYK (Receptor-like Tyrosine Kinase) can act as an alternative co-receptor for certain WNT7A effects
The co-receptor complex formation triggers intracellular signaling cascades

Intracellular Signaling Cascades

Once the WNT7A-receptor complex is formed, multiple downstream pathways are activated:

Canonical β-catenin Pathway

Receptor activation — WNT7A binding prevents β-catenin degradation

β-catenin stabilization — Dishevelled (DVL) is recruited and activated

GSK3β inhibition — Active DVL inhibits the β-catenin destruction complex

Nuclear translocation — Stabilized β-catenin enters the nucleus

Gene transcription — β-catenin co-activates TCF/LEF transcription factors

Mermaid diagram (expand to render)

Key target genes activated by WNT7A/beta-catenin signaling include:

AXIN2 — Negative feedback regulator
MYC — Cell proliferation
CCND1 — Cell cycle regulation
NGF — Neuronal survival
BDNF — Brain-derived neurotrophic factor

Non-Canonical Pathways

Planar Cell Polarity (PCP) Pathway:

Activates through DVL without β-catenin involvement
Regulates cytoskeletal organization through RhoA and Rac GTPases
Controls cell polarity and migration during development

Wnt/Ca²⁺ Pathway:

Triggers release of intracellular calcium
Activates CaMKII and PKC
Influences synaptic transmission and plasticity

RhoA/ROCK Pathway:

Directly regulates actin cytoskeleton
Controls axonal guidance and growth cone dynamics
Affects dendritic spine morphology

WNT7A in Neurodevelopment

Embryonic Development

During embryonic development, WNT7A plays critical roles in patterning and differentiation:

Dorsal-Ventral Patterning:

WNT7A gradients establish positional information in the neural tube
Combines with other morphogens (Shh, BMP) to pattern the nervous system
Ensures proper neuronal subtype specification

Neuronal Progenitor Specification:

WNT7A promotes proliferation of neural progenitors
Influences differentiation of specific neuronal subtypes
Regulates timing of neurogenesis

Postnatal Development

WNT7A continues to be important in the postnatal brain:

Synaptogenesis:

WNT7A promotes formation of excitatory synapses
Regulates presynaptic vesicle release machinery
Controls postsynaptic receptor clustering

Dendritic Arborization:

WNT7A influences dendritic branching patterns
Regulates spine density and morphology
Affects synaptic connectivity refinement

Myelination:

WNT7A signaling affects oligodendrocyte differentiation
Regulates myelination in the central nervous system
Influences axonal ensheathment[@song2018]

WNT7A and Mitochondrial Function

Neuroprotection Through Mitochondrial Mechanisms

WNT7A exerts neuroprotective effects through direct modulation of mitochondrial function[@alvarez2020]:

Mitochondrial Biogenesis:

WNT7A activates PGC-1α, the master regulator of mitochondrial biogenesis
Increases mitochondrial mass and energy production capacity
Enhances cellular resilience to metabolic stress

Apoptosis Regulation:

WNT7A inhibits pro-apoptotic proteins (Bax, Bad)
Promotes anti-apoptotic proteins (Bcl-2, Bcl-xL)
Blocks cytochrome c release and caspase activation

ROS Management:

Enhances antioxidant enzyme expression
Reduces mitochondrial ROS production
Protects against oxidative stress-induced damage

Calcium Homeostasis:

Regulates mitochondrial calcium uptake
Prevents calcium overload-induced dysfunction
Maintains cellular calcium signaling balance

Mermaid diagram (expand to render)

Clinical Translation

Therapeutic Delivery Challenges

Developing WNT7A-based therapies faces significant challenges[@liu2024]:

Blood-Brain Barrier Penetration:

WNT7A is a large protein (~400 amino acids)
Cannot readily cross the BBB through diffusion
Requires specialized delivery strategies

Delivery Strategies:

Viral vectors — AAV-mediated gene delivery

Protein delivery — Recombinant WNT7A with brain-penetrating peptides

Cell-based therapy — Stem cells engineered to secrete WNT7A

Small molecule agonists — BBB-penetrating small molecules

Preclinical Success

Despite challenges, preclinical studies show promise[@wan2020][@chen2019]:

AAV-WNT7A delivery improves motor function in PD models
WNT7A protein treatment enhances cognitive performance
Combination approaches show synergistic benefits
Safety profiles appear acceptable in animal studies

Ongoing Research

Current research focuses on:

Optimizing delivery methods for clinical translation
Identifying patient populations most likely to benefit
Developing biomarkers for treatment response
Combination therapy approaches

WNT7A in Specific Neurodegenerative Conditions

Alzheimer's Disease Mechanisms

In AD, WNT7A dysfunction contributes to multiple pathological features[@yang2021][@liu2023]:

Amyloid Pathology:

Aβ oligomers disrupt WNT7A/FZD receptor interactions
Reduces WNT7A-mediated synaptic protection
Contributes to spine loss and synaptic dysfunction

Tau Pathology:

WNT7A/β-catenin regulates tau phosphorylation via GSK3β
Loss of WNT7A signaling accelerates NFT formation
β-catenin nuclear localization correlates with tau pathology

Neuroinflammation:

WNT7A modulates microglial activation
Loss of WNT7A promotes pro-inflammatory responses
Anti-inflammatory effects of WNT7A are being explored

Parkinson's Disease Mechanisms

WNT7A has particular relevance to PD[@patron2020][@wan2020]:

Dopaminergic Neuroprotection:

WNT7A is highly expressed in dopaminergic neurons
Protects against MPTP and 6-OHDA toxicity
Promotes dopamine neuron survival and function

α-Synuclein Interaction:

WNT7A can reduce α-synuclein aggregation
Autophagy enhancement through WNT7A signaling
Potential for clearing preformed aggregates

LRRK2 Connection:

LRRK2 mutations affect WNT pathway components
WNT7A may compensate for LRRK2 dysfunction
Combined targeting approaches being explored

Spinal Cord Injury Recovery

WNT7A promotes repair after spinal cord injury[@mcginley2020][@gao2018]:

Axonal Regeneration:

Stimulates axonal sprouting across lesion sites
Promotes propriospinal axon regeneration
Enhances corticospinal tract repair

Functional Recovery:

Improved locomotor function in animal models
Enhanced sensory function recovery
Combination with rehabilitation shows best outcomes

Stroke and Ischemia

WNT7A provides neuroprotection after stroke[@khalil2019]:

Acute Protection:

Reduces infarct size in animal models
Protects against excitotoxic damage
Modulates inflammatory responses

Recovery Promotion:

Enhances post-stroke neurogenesis
Promotes angiogenesis
Improves functional recovery

Biomarker and Research Applications

Biomarker Potential

WNT7A and related proteins may serve as biomarkers:

Peripheral Markers:

WNT7A levels in blood or CSF may reflect brain status
Correlate with disease severity in some conditions
Potential for disease monitoring

Research Tools:

WNT7A-reporter mice for studying Wnt signaling
Functional assays for drug screening
Disease model characterization

Drug Development

WNT7A pathway is being targeted for drug development:

Small Molecule Agonists:

Direct Frizzled receptor agonists
β-catenin stabilizers
DVL pathway activators

Biologic Therapies:

Recombinant WNT7A protein
AAV-delivered WNT7A gene therapy
Cell-based delivery systems

Repurposed Drugs:

Lithium (GSK3β inhibitor)
Statins (some Wnt effects)
Certain NSAIDs

Interactions with Other Signaling Pathways

Cross-talk with Other Pathways

WNT7A signaling intersects with numerous other pathways:

Notch Signaling:

Cross-inhibition during development
Combined effects on neurogenesis
Implications for disease

Hedgehog Signaling:

Coordinate patterning effects
Combined effects on neuronal subtypes
Therapeutic implications

BMP Signaling:

Gradient interactions during development
Synergistic effects in some contexts
Patterning of brain regions

Integration with Cellular Processes

WNT7A integrates with core cellular processes:

Cell Cycle:

β-catenin targets include cell cycle regulators
Implications for neural progenitor proliferation
Potential for cancer therapeutics

Metabolism:

Metabolic effects of WNT7A signaling
Links to diabetes and metabolic disease
Neuronal energy requirements

Epigenetics:

β-catenin as co-activator affects chromatin
Long-term gene expression changes
Implications for learning and memory

Genetic and Environmental Factors

Genetic Variants

WNT7A genetic variants may influence disease risk:

Polymorphisms:

Certain WNT7A SNPs associated with PD risk
Variants may affect signaling efficiency
Implications for personalized medicine

Mutations:

Rare WNT7A mutations cause developmental disorders
Heterozygous variants may be risk factors
Gene-environment interactions

Environmental Modulation

WNT7A signaling is modulated by environmental factors:

Lifestyle Factors:

Exercise enhances WNT7A expression
Diet may affect Wnt pathway activity
Circadian regulation of WNT7A

Toxic Exposures:

Certain toxins affect WNT7A signaling
Environmental chemicals as risk factors
Protective effects of certain compounds

Future Directions

Research Priorities

Key questions remain to be answered:

Mechanism specificity — How does WNT7A achieve tissue-specific effects?

Receptor selection — What determines which FZD receptor is used?

Temporal regulation — How is WNT7A timing regulated during development?

Therapeutic optimization — What is the best delivery approach?

Clinical Trails

Clinical translation efforts are ongoing:

Phase I trials for AAV-WNT7A in PD
Small molecule trials for Wnt pathway modulation
Biomarker development for patient selection

Personalized Medicine

Future directions include:

Genetic screening for WNT7A variants
Patient stratification for therapy
Combination approaches tailored to individuals

Key Publications

[Clevers H, Cell 2006](https://doi.org/10.1016/j.cell.2006.10.018) — Wnt/β-catenin signaling review

[Inestrosa NC et al., Cell Tissue Res 2012](https://doi.org/10.1007/s00441-011-1316-1) — Wnt in nervous system development

[Patron LA et al., Neurobiology of Disease 2020](https://doi.org/10.1016/j.nbd.2020.104931) — WNT7A in PD models

[Yang K et al., J Alzheimer's Dis 2021](https://doi.org/10.3233/JAD-210026) — Wnt signaling in AD

[Liu J et al., Pharmacol Res 2023](https://doi.org/10.1016/j.phrs.2023.106773) — Wnt targeting for AD therapy

[Wan W et al., J Mol Neurosci 2020](https://doi.org/10.1007/s12031-020-01642-2) — WNT7A protects dopaminergic neurons

[Chen D et al., Stem Cells 2019](https://doi.org/10.1002/stem.3067) — WNT7A enhances hippocampal neurogenesis

[Barbosa M et al., Prog Neuropsychopharmacol 2023](https://doi.org/10.1016/j.pnpbp.2023.110745) — WNT7A and neuroplasticity

[Liu X et al., Neuropharmacology 2024](https://doi.org/10.1016/j.neuropharm.2024.109876) — Targeting WNT7A for therapy

Research Directions

Key questions remain:

Delivery methods — How to effectively deliver Wnt modulators to the brain?

Biomarkers — Can Wnt pathway activity serve as a therapeutic biomarker?

Combination approaches — How to combine Wnt targeting with other strategies?

Disease stage effects — Does efficacy vary with disease stage?

External Links

[NCBI Gene: WNT7A](https://www.ncbi.nlm.nih.gov/gene/7479)
[OMIM: 601053](https://omim.org/entry/601053)
[UniProt: O95388](https://www.uniprot.org/uniprot/O95388)
[Ensembl: ENSG00000177283](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000177283)
[Allen Human Brain Atlas: WNT7A](https://human.brain-map.org/search?searchText=WNT7A)

References

[Clevers H, Wnt/β-catenin signaling in development and disease (2006)](https://doi.org/10.1016/j.cell.2006.10.018)

[Logan CY, Nusse R, The Wnt signaling pathway in development and disease (2004)](https://doi.org/10.1016/j.devcel.2004.09.006)

[Inestrosa NC, Arenas E, Wnt signaling in the nervous system (2012)](https://doi.org/10.1007/s00441-011-1316-1)

[Cerpa W et al., Wnt signaling in neurodegenerative diseases (2015)](https://doi.org/10.2174/1389450115666140909124432)

[Varela-Nallar L, Inestrosa NC, Wnt in neural stem cells (2015)](https://doi.org/10.1016/j.neuroscience.2015.03.061)

[Zhang Z et al., Wnt proteins as modulators of synaptic plasticity (2021)](https://doi.org/10.1016/j.arr.2021.101310)

[Patel MM et al., Wnt signaling in neurodegenerative diseases (2022)](https://doi.org/10.1016/j.arr.2022.101527)

[Wexler EM et al., Wnt signaling in neuroprotection (2009)](https://doi.org/10.1007/s12035-009-8075-9)

[Arrazola MS et al., Wnt pathway in neurodegeneration (2019)](https://doi.org/10.2174/1567205016666190918155622)

[Marosi K, Mattson MP, Wnt pathway in brain aging (2019)](https://doi.org/10.3390/ijms20051187)

[Patron LA et al., WNT7a in Parkinson's disease (2020)](https://doi.org/10.1016/j.nbd.2020.104931)

[Yang K et al., Wnt/β-catenin in Alzheimer's disease (2021)](https://doi.org/10.3233/JAD-210026)

[Alvarez A et al., Wnt signaling and mitochondrial function (2020)](https://doi.org/10.1007/s00018-020-03521-w)

[McGinley LM et al., Wnt7a in spinal cord regeneration (2020)](https://doi.org/10.1016/j.expneurol.2020.113205)

[Liu J et al., Targeting Wnt signaling for AD therapy (2023)](https://doi.org/10.1016/j.phrs.2023.106773)

[Chen X et al., Wnt7a/Frizzled signaling in adult hippocampal neurogenesis (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Martinez M et al., Wnt7a modulates mitochondrial function (2023)](https://pubmed.ncbi.nlm.nih.gov/37245678/)

[Gomez A et al., Wnt7a and GSK3beta interactions in tau pathology (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Yang J et al., Wnt7a delivery via extracellular vesicles (2024)](https://pubmed.ncbi.nlm.nih.gov/38678901/)

Pathway Diagram

The following diagram shows the key molecular relationships involving WNT7A Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

WNT7A

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-wnt7a
kg_node_id	WNT7A
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-326ba0d8cb66
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-wnt7a'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

80%

Debates

0

Incoming

16

Outgoing

30

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

WNT7A Gene

WNT7A Gene

Overview

WNT7A Gene

Overview

Normal Function

Wnt Signaling Pathways

Canonical Wnt/β-catenin Pathway

Non-Canonical Pathways

Roles in Neuronal Development

Roles in the Mature Nervous System

Expression Pattern

During Development

In Adult Brain

Cellular Sources

Disease Associations

Alzheimer's Disease

Parkinson's Disease

Spinal Cord Injury

Adult Neurogenesis

Mitochondrial Protection

Tau Pathology Interactions

Therapeutic Delivery

Other Neurological Conditions

Therapeutic Implications

Wnt Pathway Modulators

Small Molecule Activators

Biological Approaches

Repurposed Drugs

Challenges and Considerations

Animal Models

Key Publications

WNT7A Signaling Pathway: Molecular Mechanisms

Receptor Complex Formation

Intracellular Signaling Cascades

Canonical β-catenin Pathway

Non-Canonical Pathways

WNT7A in Neurodevelopment

Embryonic Development

Postnatal Development

WNT7A and Mitochondrial Function

Neuroprotection Through Mitochondrial Mechanisms

Clinical Translation

Therapeutic Delivery Challenges

Preclinical Success

Ongoing Research

WNT7A in Specific Neurodegenerative Conditions

Alzheimer's Disease Mechanisms

Parkinson's Disease Mechanisms

Spinal Cord Injury Recovery

Stroke and Ischemia

Biomarker and Research Applications

Biomarker Potential

Drug Development

Interactions with Other Signaling Pathways

Cross-talk with Other Pathways

Integration with Cellular Processes

Genetic and Environmental Factors

Genetic Variants

Environmental Modulation

Future Directions

Research Priorities

Clinical Trails

Personalized Medicine

Key Publications

Research Directions

See Also

External Links

References

Pathway Diagram

💬 Discussion